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Ulcerative colitis is one of the few diseases in which smoking appears to confer some benefit (1). We report a 
patient whose ulcerative colitis deteriorated on several occasions on stopping cigarettes, and improved on 
restarting smoking. As a result, she continued smoking despite developing airflow limitation and severe 
emphysema. She was subsequently found to have a 1 anti-trypsin deficiency. She later noticed that she could 
get a similar benefit in her colitis with nicotine chewing gum as she had with cigarettes. For patients with 
smoking-responsive ulcerative colitis, non-tobacco forms of nicotine delivery such as gum or transdermal 
patches should be considered to avoid the hazards of cigarette smoke. 
Case Report 
A woman born in 1927 smoked about 25 cigarettes 
daily from the age of 12 years (1939) until 1966, 
when she attempted to give up smoking following a 
pneumothorax. About this time, she had her first 
attack of bloody diarrhoea. She restarted smoking. 
Between 1972-1975, she had three further episodes 
of gastrointestinal disturbance. She observed that 
each bout came on IO-14 days after attempting to 
give up smoking, and resolved 2-3 weeks after 
restarting. The problem had been diagnosed initially 
as diverticulitis, but in 1975 a clinical diagnosis 
of ulcerative colitis was made, which was later 
confirmed by colonoscopic biopsy. 
She restarted smoking later in 1975 and her 
gastrointestinal symptoms settled. However, she 
began to suffer respiratory symptoms and in 1979 
lung function testing showed FEV, 1.17 1 (51% 
of predicted), total lung capacity 5.41 1 (117% of 
predicted) and residual volume 3.29 1 (209% of 
predicted). Despite this, she continued to smoke for 
seven more years. 
In 1985, sigmoidoscopy showed only slight oedema 
to 5 cm with no active colitis. However in February 
1986 she again stopped smoking, her ulcerative colitis 
flared up and colonoscopy showed active colitis to 
30 cm. This initially improved with predsol supposi- 
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tories, but in June 1986 she relapsed. She was unable 
to tolerate sulphasalazine or mesalazine. 
In October 1986, she started using nicotine 
chewing gum 34 times day - i. Her bowel symptoms 
settled after 34 days. This was faster than on previ- 
ous occasions when she had smoked cigarettes. She 
continued to take nicotine gum for 4 weeks. From 
that time onwards, she used nicotine chewing gum 
‘pm’ when she felt that a bout of colitis was com- 
mencing. She was on no other regular medication 
and remained well except for one episode in 1987 
during a period of severe emotional stress, which did 
not respond to the nicotine and was treated with 
prednisolone. 
Although she did not smoke again, her breathing 
problems led to referral to our department in 1988. 
At this time, lung function testing showed FEV, 0.61 
(28% of predicted), FVC 1.56 (58% of predicted), 
residual volume 2.37 1 (134% of predicted) and KC0 
0.91 (41% of predicted). She reported that her father 
and her daughter also suffered from emphysema. Her 
a 1 anti-trypsin level was low at 1.10 g I- ’ (normal 
range 1.43.4 g I- I). She was treated with inhaled 
bronchodilators, budesonide and a short course of 
oral steroid with some improvement in lung function, 
but her best was only FEV, 0.75 1(35% of predicted), 
FVC 1.8 1 (67% of predicted). 
In March 1990 during a holiday in Thailand, her 
colitis symptoms became worse and persisted, despite 
nicotine. Blood was coming from higher in the colon 
than before and in June 1990 a barium enema showed 
total colitis. In view of the duration of her illness and 
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risk of colonic carcinoma, she underwent a total 
colectomy in July 1990. 
Discussion 
There have been attempts by opponents of tobacco 
control to divert attention away from the dangers of 
smoking by seeking to highlight health ‘benefits’. 
Ulcerative colitis is one of the few diseases which is 
less common among smokers (2,3), and in which 
smoking may confer benefit (1). Our patient had been 
unable to give up cigarettes despite several attempts 
because cessation of smoking led to exacerbations of 
her ulcerative colitis. She developed severe emphy- 
sema as a result of prolonged heavy smoking in 
association with a 1 anti-trypsin deficiency. She later 
found that she got the same beneficial effect on her 
colitis with nicotine chewing gum. Although eventu- 
ally nicotine gum failed to prevent a colectomy, it 
had kept her well for 4 years when other treatments 
had failed. 
A previous case of using nicotine chewing gum for 
ulcerative colitis was reported in 1982 (4). Subse- 
quently, three trials of therapeutic use of nicotine 
have been reported with varying results. In an open, 
uncontrolled study, three out of 11 patients had 
symptomatic improvement but no change in sig- 
moidoscopic appearance (5). Of seven patients under- 
going blind cross-over single patient trials, three 
former smokers improved on nicotine chewing gum 
compared with placebo (6). A randomized placebo 
controlled trial showed improvement of ulcerative 
colitis with transdermal nicotine patches (7). 
Nicotine is considered to be the most likely 
mediator of the beneficial effects of cigarette smoking 
in ulcerative colitis (8), with effects on mucosal blood 
flow (9), and, in animal experiments, effects on rectal 
mucosal eicosanoid and mucus production (10). 
Preliminary studies suggest that there may be 
potential for a therapeutic role of nicotine in other 
conditions for which smoking is reported to confer 
some protection, including Parkinson’s disease (1 l), 
Alzheimer’s disease (12), Tourette’s disorder (13), 
aphthous ulcers (14), and sleep disordered 
breathing (15). 
Although nicotine is not without side-effects (5-7), 
nicotine patches and chewing gum are safer than 
cigarettes, as our patient illustrates. While the place 
of nicotine as a treatment for ulcerative colitis is still 
unclear (S), a trial of nicotine chewing gum or 
transdermal patches should be considered for 
patients who find that stopping smoking causes 
an exacerbation of their ulcerative colitis, and 
perhaps other conditions, particularly if they have 
other risk factors for, or evidence of, developing 
smoking-related diseases. 
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